SEP 18, 2018 09:20 PM PDT

More Challenges in Immunotherapeutic Developments

WRITTEN BY: Nouran Amin

Image via BioTech Stocks

Fighting disease using the immune system is the body’s most prized possession and it does so by utilizing immunotherapy. However, a discovery by researchers at the University of Notre Dame has found a challenge in creating molecules for immunotherapy for the purpose of drug development. More specifically, researchers found two different peptide antigens that react with one T-cell receptor (TCR) according to the study published in Nature Chemical Biology.

"Essentially, we discovered that T-cell receptors can be much more cross-reactive than we previously envisioned, which is somewhat concerning for the entire field," explains lead author Timothy Riley.

Considered a subtype of white blood cells, T cells are responsible for detecting any changes in our immune health. However, they do not always detect cancer cells; ignoring their potential threat. For T-cell immunotherapy, targeted cells are altered to contain receptors that allow T cell recognition of ‘dangerous’ cells. Although this particular immunotherapeutic is effective, it can also attack and destroy healthy cells. Thus, scientists have been seeking to predict reactivity and to ensure that T cells recognize only the targeted cells by delving deeper into the TCR analysis.

To learn more about T-cells and TCR, watch the video below:

"We thought the TCR was ignoring small differences (in the highly charged target) a little bit, and simply found things similar to recognize," says Brian Baker, the John A. Zahm, C.S.C., Professor of Structural Biology and chair of the Department of Chemistry and Biochemistry. "But that was wrong. We discovered that this peptide moved and adapted in order for the receptor to bind, in a way that no one had seen before."

These two different proteins, or peptide antigens, worked at the same level for binding specificity with DMF5, where they stimulated the receptor and induced an immune response. "It doesn't really matter how it works, as long as binding occurs," Riley said.

The research findings have advanced our understanding of how to develop immunotherapies in the realm of drug discovery, but remains a hurdle to overcome. "What's significant is that people try to make predictions for developing these models for therapy, and about the kinds of ways you can recognize targets," explains Riley. "Now that we have great examples of a T-cell receptor recognizing multiple peptide antigens that are structurally different, we can use them to build hypotheses and test predictions."

Source: University of Notre Dame

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 20, 2019
Drug Discovery & Development
SEP 20, 2019
Drug Compound May Treat Common Genetic Kidney Disease
Researchers from the University of Sheffield in collaboration with Glasgow-based biotech company Mironid, have developed a new class of drugs for treating ...
SEP 20, 2019
Genetics & Genomics
SEP 20, 2019
Combination Therapy Eliminates HIV From Rodent Model
In 2017, 1.8 million new cases of HIV infection were diagnosed around the world, and around 37 million people live with the virus....
SEP 20, 2019
Cell & Molecular Biology
SEP 20, 2019
Relieving a Mechanism That Could Underlie as Many as 20 Rare Disorders
Toxic proteinopathies are a group of inherited diseases that are caused when improperly folded proteins accumulate in the cell....
SEP 20, 2019
Immunology
SEP 20, 2019
Making Opioids Safer
The opioid crisis results in 130 American deaths every day, and both prescribed and synthetic opioids are at the core of the epidemic.  Any other drug...
SEP 20, 2019
Drug Discovery & Development
SEP 20, 2019
The Three Drugs that Reverse Biological Aging
In the last 100 years, life expectancy in the US has risen from 55 years until 79 (Roser: 2019). And with the continuous development of medicine and scie...
SEP 20, 2019
Drug Discovery & Development
SEP 20, 2019
How Does Ketamine Treat Depression?
In recent years, ketamine has received growing interest for its neuroprotective effects. Known to alleviate symptoms of depression in just hours whereas co...
Loading Comments...